2018
DOI: 10.1080/1120009x.2018.1522472
|View full text |Cite
|
Sign up to set email alerts
|

Acute kidney injury: an unusual complication of posaconazole use

Abstract: Denning and family hold Founder shares in F2G Ltd., a University of Manchester spinout antifungal discovery company, in Novocyt which markets the Myconostica real-time molecular assays. He acts or has recently acted as a consultant to Astellas,

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 12 publications
(9 reference statements)
0
3
0
Order By: Relevance
“…The antifungal of choice is liposomal amphotericin B, which was used in our case 4 15. Posaconazole has also shown favourable outcomes and thought to be the most favourable alternative to amphotericin B, and is less likely to cause renal toxicity 4 16…”
Section: Discussionmentioning
confidence: 88%
“…The antifungal of choice is liposomal amphotericin B, which was used in our case 4 15. Posaconazole has also shown favourable outcomes and thought to be the most favourable alternative to amphotericin B, and is less likely to cause renal toxicity 4 16…”
Section: Discussionmentioning
confidence: 88%
“…Posaconazole has a relatively safe renal side effects profile. Only one case of AKI has been reported with posaconazole so far [9]. The histology was not shared as a renal biopsy was not performed, and the renal functions of the patient improved after stopping posaconazole.…”
Section: Discussionmentioning
confidence: 98%
“…Only one case of acute kidney injury (AKI) caused by posaconazole has been reported where a renal biopsy was not performed, and the renal function improved after stopping posaconazole [9].…”
Section: Introductionmentioning
confidence: 99%